drugset / Trial / NCT02568319

Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects

NCT02568319

Phase 2 Completed 120 enrolled Neothetics, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multi-center, randomized, placebo-controlled, double-blind study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging in obese subjects.

Timeline

Start
2015-09
Primary completion
2015-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Salmeterol Other / unclassified